Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.
about
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience.
P2860
Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Epoetin zeta in the management ...... macology and clinical utility.
@ast
Epoetin zeta in the management ...... macology and clinical utility.
@en
type
label
Epoetin zeta in the management ...... macology and clinical utility.
@ast
Epoetin zeta in the management ...... macology and clinical utility.
@en
prefLabel
Epoetin zeta in the management ...... macology and clinical utility.
@ast
Epoetin zeta in the management ...... macology and clinical utility.
@en
P2860
P50
P356
P1476
Epoetin zeta in the management ...... rmacology and clinical utility
@en
P2093
Mary Lynn Davis-Ajami
P2860
P304
P356
10.2147/BTT.S27578
P577
2014-04-16T00:00:00Z